panitumumab for Colorectal Cancer

Phase-Based Progress Estimates
1
Effectiveness
2
Safety
Colorectal Cancer+1 More
panitumumab - Drug
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

This trial is testing if adding Panitumumab to the usual treatments for this cancer will help keep it in remission for longer.

Eligible Conditions
  • Colorectal Cancer
  • Metastatic Colorectal Cancer (CRC)

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

1 Primary · 3 Secondary · Reporting Duration: 2 years

2 years
to analyze tumor tissue for predictive biomarkers
to determine if panitumumab with Hepatic Arterial Infusion (HAI) in combination with systemic chemotherapy can increase the recurrence free survival (RFS) for colorectal cancer patients with resected liver metastases
to determine survival
Day 1
to assess toxicity as per the NCI Common Toxicity Criteria

Trial Safety

Safety Progress

2 of 3
This is further along than 68% of similar trials

Side Effects for

Panitumumab
94%Dysphagia
92%Acne
92%Dry mouth
87%Taste alteration
80%Weight loss
77%Fatigue
75%Mucositis (clinical exam) Oral cavity
71%Constipation
59%Nausea
54%Pain Throat/pharynx/larynx
50%Dermatitis Chemoradiation
47%Voice changes
45%Dermatitis Radiation
43%Anorexia
42%Salivary gland changes
42%Edema: head and neck
40%Vomiting
37%Dry skin
35%Mucositis (functional/symptomatic) Oral cavity
33%Mucositis (clinical exam) Pharynx
31%Alopecia
30%Heartburn
29%Insomnia
28%Pain Oral cavity
25%Infection - Other
25%Diarrhea
24%Dehydration
24%Cough
22%Dermatology - Other
21%Lymphopenia
21%Pain Head/headache
21%Hyperpigmentation
20%Mood alteration Anxiety
20%Edema, larynx
18%Pain Middle ear
18%Pain Neck
18%Pain - Other
16%Hand-foot
15%Neuropathy-sensory
14%Hypothyroidism
14%Rigors/chills
14%Trismus
14%Hypertension
13%Hearing (without monitoring program)
11%Fever
11%Fibrosis-deep connective tissue
11%Tinnitus
11%Pruritus
11%Pain Tumor pain
10%GI - Other
10%Dyspnea
8%Mood alteration Depression
8%Rash
8%Pain Abdomen NOS
7%Muscle weakness Whole body/generalized
7%Hypopigmentation
7%Pain Back
6%Infection with normal ANC Catheter-related
6%Telangiectasia
6%Induration
6%Sweating
6%Pain Joint
6%Osteonecrosis
6%Pain Bone
6%Dizziness
6%Chelitis
6%Dry eye
5%Pain External ear
5%Neuropathy-motor
4%Edema: limb
4%Teeth
3%Hiccoughs
3%Hearing (monitoring program)
1%Pain Extremity-limb
This histogram enumerates side effects from a completed 2017 Phase 3 trial (NCT00820248) in the Panitumumab ARM group. Side effects include: Dysphagia with 94%, Acne with 92%, Dry mouth with 92%, Taste alteration with 87%, Weight loss with 80%.

Trial Design

2 Treatment Groups

Randomization to No Panitumumab
1 of 2
Randomization to panitumumab
1 of 2
Experimental Treatment

75 Total Participants · 2 Treatment Groups

Primary Treatment: panitumumab · No Placebo Group · Phase 2

Randomization to No Panitumumab
Drug
Experimental Group · 1 Intervention: Randomization to No Panitumumab · Intervention Types: Drug
Randomization to panitumumab
Drug
Experimental Group · 1 Intervention: panitumumab · Intervention Types: Drug
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Panitumumab
FDA approved

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: 2 years

Who is running the clinical trial?

Memorial Sloan Kettering Cancer CenterLead Sponsor
1,821 Previous Clinical Trials
584,272 Total Patients Enrolled
AmgenIndustry Sponsor
1,291 Previous Clinical Trials
1,306,979 Total Patients Enrolled
Nancy Kemeny, MDPrincipal InvestigatorMemorial Sloan Kettering Cancer Center
2 Previous Clinical Trials
87 Total Patients Enrolled

Eligibility Criteria

Age 18+ · All Participants · 10 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 10th, 2021

Last Reviewed: October 21st, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.